Notes · Surgery · 4 November 2026

Acute mesenteric ischemia

Definition

• Acute mesenteric ischemia (AMI) is a sudden reduction in blood flow to the small intestine, leading to intestinal hypoxia, cellular injury, and if untreated, transmural necrosis.
• It is a surgical emergency that requires rapid diagnosis and treatment to prevent high mortality.

Epidemiology

• Incidence is approximately 1–2 cases per 100,000 population per year, increasing with age.
• Median age at presentation is 70 years; >70 % of patients are older than 60 years.
• Male predominance (≈ 2 : 1) is reported, largely due to higher prevalence of atherosclerotic disease and atrial fibrillation in men.
• Mortality remains high (60–80 %) despite advances in imaging and endovascular therapy.

Aetiology (Causes)

• Arterial embolism (≈ 50 %): Most common; emboli usually arise from the left atrium in atrial fibrillation, left ventricular thrombus, or valvular disease and lodge at the origin of the superior mesenteric artery (SMA).
• Arterial thrombosis (≈ 25 %): In‑situ thrombosis on a pre‑existing atherosclerotic plaque of the SMA, often precipitated by hypotension or a hypercoagulable state.
• Non‑occlusive mesenteric ischemia (NOMI) (≈ 20 %): Splanchnic vasoconstriction secondary to low cardiac output, sepsis, or vasoactive drugs; no anatomic obstruction.
• Venous thrombosis (≈ 5 %): Mesenteric venous thrombosis (MVT) due to hypercoagulable states, portal hypertension, or intra‑abdominal inflammation.

Pathophysiology

• Ischemic cascade: Sudden loss of arterial inflow → ↓ oxygen delivery → anaerobic metabolism → lactate accumulation → cellular acidosis → loss of ATP → disruption of Na⁺/K⁺ pumps → cellular swelling and death.
• Reperfusion injury: Restoration of flow generates reactive oxygen species, causing further endothelial damage, increased permeability, and systemic inflammatory response.
• Transmural necrosis: When ischemia persists > 6 hours, the mucosal barrier breaks down, allowing bacterial translocation and sepsis.
• NOMI mechanism: Splanchnic vasoconstriction mediated by sympathetic over‑activity and endothelin release; the SMA is most vulnerable because it supplies a large portion of the small bowel with relatively low collateral flow.

Clinical Features

• Pain: Sudden, severe, diffuse abdominal pain that is “out of proportion” to physical findings; patients often describe it as a tearing or cramping sensation.
• Gastro‑intestinal signs: Early on, abdomen may be soft with minimal guarding; later, peritoneal signs (rigidity, rebound tenderness) develop as necrosis progresses.
• Systemic signs: Nausea, vomiting (often bilious), diarrhea or melena, tachycardia, hypotension, fever, and signs of shock in advanced disease.
• Risk‑factor clues: History of atrial fibrillation, recent myocardial infarction, heart failure, atherosclerosis, recent major surgery, or use of vasoconstrictors.

Investigations

Management (2024 Guidelines – American College of Surgeons, European Society of Vascular Surgery)

1. Immediate Resuscitation

   • Secure airway, provide supplemental O₂ to maintain SpO₂ ≥ 94 %.
   • Large‑bore IV access; give isotonic crystalloids (e.g., 20 mL/kg bolus) to restore intravascular volume.
   • Target MAP ≥ 65 mmHg; use norepinephrine only if fluid resuscitation fails.

2. Broad‑Spectrum Antibiotics

   • Start empiric coverage (e.g., piperacillin‑tazobactam 4.5 g IV q6h) to prevent bacterial translocation‑related sepsis.

3. Anticoagulation

   • Unfractionated heparin bolus 80 U/kg IV, then infusion to maintain aPTT 1.5–2.5 × control.
   • For patients with contraindication to heparin, use low‑molecular‑weight heparin (enoxaparin 1 mg/kg SC q12h) if bleeding risk acceptable.

4. Revascularization Strategy

   • Arterial embolism:
     • Endovascular embolectomy or catheter‑directed thrombolysis (tPA 0.5–1 mg/h) is first‑line if within 6 h and no peritonitis.
     • Open embolectomy (SMA thrombectomy) if endovascular fails or patient unstable.
   • Arterial thrombosis:
     • Endovascular angioplasty ± stent placement preferred; adjunctive intra‑arterial thrombolysis if clot burden large.
     • Immediate laparotomy with SMA bypass (e.g., aorto‑SM bypass) if bowel viability uncertain.
   • NOMI:
     • Optimize cardiac output, discontinue vasoconstrictors, give intra‑arterial papaverine (30 mg bolus then 30 mg/h infusion) via SMA catheter.
   • Mesenteric venous thrombosis:
     • Systemic anticoagulation (heparin) is mainstay; consider catheter‑directed thrombolysis if extensive clot and worsening.

5. Assessment of Bowel Viability

   • Intra‑operative: color, peristalsis, arterial pulsation, fluorescein dye with Wood’s lamp.
   • If non‑viable segment identified, perform resection with primary anastomosis if patient stable; otherwise, create stoma.

6. Post‑operative Care

   • Continue anticoagulation (transition to warfarin with INR 2–3 or DOAC if appropriate).
   • Monitor lactate trends; decreasing lactate indicates reperfusion success.
   • Nutritional support: early enteral feeding if feasible; otherwise, parenteral nutrition.

7. Follow‑up Imaging

   • Duplex or CTA at 48–72 h to confirm patency of revascularized vessel and detect early re‑occlusion.

Complications

• Bowel necrosis → perforation, peritonitis, septic shock.
• Short‑bowel syndrome after extensive resection, leading to malabsorption and need for long‑term parenteral nutrition.
• Re‑occlusion of the SMA (up to 15 % within 30 days) requiring repeat intervention.
• Systemic complications: Acute kidney injury from hypotension, disseminated intravascular coagulation, and multi‑organ failure.
• Post‑operative wound infection and anastomotic leak, especially in hemodynamically unstable patients.

High‑Yield Exam Points

• Pain out of proportion is the classic hallmark of AMI.
• Most common cause: arterial embolism from atrial fibrillation lodging at the SMA origin.
• Gold‑standard diagnostic test: contrast‑enhanced CT angiography.
• Early laboratory clue: serum lactate > 2 mmol/L with metabolic acidosis.
• Initial medical therapy: aggressive fluid resuscitation, broad‑spectrum antibiotics, and IV heparin.
• Endovascular first for embolic or thrombotic occlusion when no peritonitis; open surgery reserved for bowel necrosis or failed endovascular attempt.
• NOMI is associated with low‑output states and vasopressor use; treatment focuses on improving cardiac output and intra‑arterial vasodilators.
• Mortality reduction is linked to time to revascularization; aim for < 6 h from symptom onset.

Practice questions

1. A 72‑year‑old man with known atrial fibrillation presents with sudden severe abdominal pain disproportionate to exam findings. CT angiography shows an abrupt cutoff of the SMA 2 cm distal to its origin. Which of the following is the most appropriate initial definitive therapy?

   • A) Immediate laparotomy with bowel resection
   • B) Endovascular embolectomy with catheter‑directed thrombolysis
   • C) High‑dose intravenous steroids
   • D) Observation and analgesia

   Answer: B — endovascular embolectomy is first‑line for embolic SMA occlusion when there is no peritonitis.

2. Which laboratory abnormality is most specific for early intestinal ischemia in a patient with suspected acute mesenteric ischemia?

   • A) Elevated serum amylase
   • B) Leukocytosis > 15 × 10⁹/L
   • C) Serum lactate > 2 mmol/L
   • D) Hyperbilirubinemia

   Answer: C — rising lactate reflects anaerobic metabolism and is a sensitive early marker of tissue hypoperfusion.

3. A patient with severe sepsis on high‑dose norepinephrine develops new abdominal pain. CT shows diffuse bowel wall thickening without arterial occlusion. The most likely diagnosis is:

   • A) Arterial embolism
   • B) Mesenteric venous thrombosis
   • C) Non‑occlusive mesenteric ischemia (NOMI)
   • D) Acute pancreatitis

   Answer: C — NOMI occurs in low‑flow states and vasopressor use, producing bowel changes without a visible arterial blockage.

More in Surgery

AI-assisted study material for exam revision. Always confirm with standard textbooks and current guidelines; not medical advice.